Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9.
Purity:
>95.0%
CAS Number:
[1643672-70-1]
Target:
PCSK9
* VAT and and shipping costs not included. Errors and price changes excepted